Clinical Trial Update: 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) [NA]

View source ↗

Summary

The PROMPT clinical trial is currently recruiting to compare 5500/20 therapy against SABR or brachytherapy for primary treatment of oligometastatic prostate can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Oligometastatic Prostate Cancer | NA | Status: RECRUITING